As of 2026-05-15, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (4,095.39) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -48281.1%.
The range of the Relative Valuation is (3,725.76) - (4,238.21) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.7x - 21.7x | 19.3x |
| Forward P/E multiples | 16.9x - 20.2x | 19.7x |
| Fair Price | (3,725.76) - (4,238.21) | (4,095.39) |
| Upside | -43932.5% - -49961.3% | -48281.1% |
| Date | P/E |